IntraLuminal Therapeutics Inc., of Carlsbad, Calif., appointed Michael Eagle executive chairman.

Kalypsys, of San Diego, promoted Court Turner to vice president, strategic alliances and senior legal counsel; Stewart Noble to vice president, discovery chemistry; and Andy Shiau to director of biology.

Lev Pharmaceuticals Inc., of New York, appointed Douglas Beck chief financial officer.

Linguagen Corp., of Cranbury, N.J., appointed Bernd Nilius to its scientific advisory board.

Lipid Sciences Inc., of Pleasanton, Calif., appointed Bryan Brewer vice chairman of its board.

Lipoxen Technologies Ltd., of London, appointed Brian Richards to its board.

Luminex Corp., of Austin, Texas, appointed Russell Bradley vice president, business development and strategic planning.

MediVas LLC, of San Diego, appointed Joseph Dowling executive vice president and chief financial officer.

Merrimack Pharmaceuticals, of Cambridge, Mass., appointed Dan Littman and James Marks to its scientific advisory board.

Metabolex Inc., of Hayward, Calif., appointed Patrick James Doyle chief corporate development officer.

Molecular Insight Pharmaceuticals Inc., of Cambridge, Mass., appointed James Wachholz vice president, regulatory affairs and quality assurance, and Joshua Hamermesh vice president, commercial and business development.

Momenta Pharmaceuticals Inc., of Cambridge, Mass., appointed Barbara Rosengren vice president, strategic product development.

Nabi Biopharmaceuticals, of Boca Raton, Fla., appointed Stephan Lawton vice president, government relations.

Neovacs, of Paris, appointed Jean-Jacques Bertrand chairman.

Nonlinear Dynamics, of Newcastle Upon Tyne, UK, appointed Stephen David to its strategic marketing team.

Nuvelo Inc., of Sunnyvale, Calif., appointed Michael Fleming vice president, commercial operations.

OccuLogix Inc., of Toronto, appointed John Caloz chief financial officer and treasurer.

Pharmacyclics Inc., of Sunnyvale, Calif., appointed Geoffrey Cooper senior vice president, business development.

PharmaFrontiers Corp., of The Woodlands, Texas, appointed Norman Barton, Daniel Marshak and Shelly Heimfeld to its scientific advisory board.

Pharmion Corp., of Boulder, Colo., appointed John Reed to its board.

Predix Pharmaceuticals, of Lexington, Mass., appointed Ian Smith to its board.

Prometic Life Sciences Inc., of Montreal, appointed Stephane Archambault vice president of finance, Vincent Taillefer vice president of corporate development, and Janis Peleshok director of business development.

No Comments